ATE253593T1 - Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit - Google Patents

Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit

Info

Publication number
ATE253593T1
ATE253593T1 AT97934467T AT97934467T ATE253593T1 AT E253593 T1 ATE253593 T1 AT E253593T1 AT 97934467 T AT97934467 T AT 97934467T AT 97934467 T AT97934467 T AT 97934467T AT E253593 T1 ATE253593 T1 AT E253593T1
Authority
AT
Austria
Prior art keywords
igsf
domains
fragments
modification
fusion proteins
Prior art date
Application number
AT97934467T
Other languages
English (en)
Inventor
Andreas Plueckthun
Lars Nieba
Annemarie Honegger
Original Assignee
Plueckthun Andreas Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plueckthun Andreas Prof Dr filed Critical Plueckthun Andreas Prof Dr
Application granted granted Critical
Publication of ATE253593T1 publication Critical patent/ATE253593T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97934467T 1996-07-16 1997-07-16 Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit ATE253593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111441 1996-07-16
PCT/EP1997/003792 WO1998002462A1 (en) 1996-07-16 1997-07-16 Immunoglobulin superfamily domains and fragments with increased solubility

Publications (1)

Publication Number Publication Date
ATE253593T1 true ATE253593T1 (de) 2003-11-15

Family

ID=8222993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934467T ATE253593T1 (de) 1996-07-16 1997-07-16 Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit

Country Status (7)

Country Link
US (1) US6815540B1 (de)
EP (1) EP0938506B1 (de)
JP (1) JP2000516452A (de)
AT (1) ATE253593T1 (de)
CA (1) CA2267620A1 (de)
DE (1) DE69726003T2 (de)
WO (1) WO1998002462A1 (de)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0866805A1 (de) 1995-12-12 1998-09-30 Karolinska Innovations AB Peptide, das die KLVFF Sequenz von beta-Amyloid bindet
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EP1131428A2 (de) * 1998-11-19 2001-09-12 Incyte Pharmaceuticals, Inc. Proteine der immunoglobulin-superfamilie
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1600459A3 (de) * 2002-06-28 2005-12-07 Domantis Limited Ligand
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP1824961B1 (de) 2004-12-07 2016-11-02 Lonza Ltd System zur expression von melibiose-operon
ATE466090T1 (de) 2004-12-07 2010-05-15 Lonza Ag Rhamnosepromotor-expressionssystem
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP2395026B1 (de) * 2005-02-08 2018-01-24 The Chemo-Sero-Therapeutic Research Institute Verfahren zur Verbesserung eines Antikörpers
EP2295080A3 (de) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2013236B1 (de) 2006-04-28 2015-06-17 Delenex Therapeutics AG An die extrazelluläre domäne der rezeptortyrosinkinase alk bindende antikörper
TW200813087A (en) * 2006-05-31 2008-03-16 Astellas Pharma Inc Humanized anti-human osteopontin antibody
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
SG186017A1 (en) 2007-11-30 2012-12-28 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
AU2013203477B2 (en) * 2008-06-25 2015-02-12 Novartis Ag Solubility optimization of immunobinders
US9556265B2 (en) 2008-06-25 2017-01-31 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
ES2771150T3 (es) * 2008-06-25 2020-07-06 Novartis Ag Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
RU2577965C2 (ru) * 2009-02-24 2016-03-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Способ идентификации иммунных связывающих веществ поверхностных антигенов клетки
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
WO2011075861A1 (en) * 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA2858350A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
EP3458856B1 (de) * 2016-05-19 2021-04-21 Wisconsin Alumni Research Foundation Verfahren, systeme und zusammensetzungen zur untersuchung der lösungsmittelzugänglichkeit und dreidimensionalen struktur biologischer moleküle
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
EP3864039B1 (de) * 2018-10-08 2023-12-06 The UAB Research Foundation Gezielte therapie von neuroendokrinem krebs
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
CN117222656A (zh) * 2021-05-03 2023-12-12 安捷伦科技有限公司 嵌合免疫原和用于制备针对特定表位的多克隆抗体的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions

Also Published As

Publication number Publication date
EP0938506A1 (de) 1999-09-01
DE69726003T2 (de) 2004-08-26
EP0938506B1 (de) 2003-11-05
JP2000516452A (ja) 2000-12-12
CA2267620A1 (en) 1998-01-22
DE69726003D1 (de) 2003-12-11
WO1998002462A1 (en) 1998-01-22
US6815540B1 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
DE69726003D1 (de) Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
WO1999055868A3 (en) Fizz proteins
Bhakdi et al. Isolation of the terminal complement complex from target sheep erythrocyte membranes
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
CA2068222A1 (en) Monoclonal antibodies
Journet et al. Requirement for Both D Domains of the Propolypeptide in von Willebrand Factor Muitimerization and Storage
AU2002363465A1 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DE69611896D1 (de) Fusions-DNS-Sequenz, dadurch exprimiertes Fusionsprotein und Verfahren zur Expression dieses Fusionsproteins
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
ZA200007619B (en) New peptide fragments for protein purification.
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
Kumazaki et al. Comparative study on fibers isolated from four R-type pyocins, phage-tail-like bacteriocins of Pseudomonas aeruginosa
WO2001014536A3 (de) Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz
WO1999042586A3 (en) Exo1 and exo2, exocytotic proteins
EP1241179A3 (de) Menschliches Cornichon-ähliches Protein und dafür kodierende Nukleinsäure
DK1270590T3 (da) Protein, som fremmer overlevelse af stavformede fotoreceptorceller og nucleinsyre kodende herfor
EP1251139A3 (de) Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure
EP2050762A3 (de) Neue Polypeptide und für diese kodierende Nukleinsäuren
Matsugu et al. Improved antigen detection on western blots
DK1241251T3 (da) Humant prostasin-lignende protein og nukleinsyrer kodende for samme
EP1241252A3 (de) Menschliches Enteropeptidase-ähnliches Protein und dafür kodierende Nukleinsäure
EP1247817A3 (de) Menschliches CD-23-ähliches Protein und dafür kodierende Nukleinsäure
AU2001294399A1 (en) Heavy chain libraries
EP1241184A3 (de) Menschliches Synaptogyrin-ähnliches Protein und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0938506

Country of ref document: EP

REN Ceased due to non-payment of the annual fee